Imatinib Mesylate (STI571)

Catalog No.S1026 Synonyms: CGP-57148B, ST-1571 Mesylate

Imatinib Mesylate (STI571) Chemical Structure

Molecular Weight(MW): 589.71

Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 97 In stock
USD 197 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 38 Publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.
Targets
PDGFR [1]
(Cell-free assay)
c-Kit [2]
(M-07e cells)
v-Abl [1]
(Cell-free assay)
100 nM 100 nM 600 nM
In vitro

In vitro assays for inhibition of a panel of tyrosine and serine/threonine protein kinases show that Imatinib inhibits the v-Abl tyrosine kinase and PDGFR potently with an IC50 of 0.6 and 0.1 μM, respectively. [1] Imatinib inhibits the SLF-dependent activation of wild-type c-kit kinase activity with a IC50 for these effects of approximately 0.1 μM, which is similar to the concentration required for inhibition of PDGFR. [2] Imatinib exhibits growth-inhibitory activity on the human bronchial carcinoid cell line NCI-H727 and the human pancreatic carcinoid cell line BON-1 with an IC50 of 32.4 and 32.8 μM, respectively. [3] A recent study shows that Imatinib has the potential to exert its antileukemia effects in chronic myelogenous leukemia by down-regulating hERG1 K(+) channels, which are highly expressed in leukemia cells and appear of exceptional importance in favoring leukemogenesis. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T47D  NVvSW2FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[zTWM2OD13MDFOwG0> NVL5VJhNOjV6NkOyN|I>
Hep G2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTEUXVKSzVyPUOxJO69VQ>? MWKyOVg3OzJ|Mh?=
DU145 NUjsO2k{S2WubDDWbYFjcWyrdImgRZN{[Xl? NX7yeHVIOjEkgJpOwG0> NGPP[Ig3NTd{IHi= MljF[IVkemWjc3XzJINmdGxidnnhZoltcXS7 NE\6OJAzPTd6Nk[1Oi=>
PC3  MmX2R4VtdCCYaXHibYxqfHliQYPzZZk> NILUOW8zOOLCid88US=> NFzaZYk3NTd{IHi= MonFbY5kemWjc3XzJINmdGxidnnhZoltcXS7 M17GdFI2Pzh4NkW2
DU145 NXrsVY1pSXCxcITvd4l{KEG|c3H5 MoP0NlDjiIoQvF2= MWm0PE84OiCq MV\pcoR2[2W|IHPlcIwh\GWjdHigZpkh[XCxcITvd4l{ MkTnNlU4QDZ4NU[=
PC3  M4nSTGFxd3C2b4Ppd{BCe3OjeR?= MXqyNQKBkc7:TR?= MlfGOFgwPzJiaB?= NED2b4dqdmO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= MkjjNlU4QDZ4NU[=
MCF-7 M2TtRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKxNEDPxE1? MkezOFghcA>? MX3icI9kc3NiY3XscEBxem:uaX\ldoF1cW:wIHnuZ5Jm[XOnIHnu[JVk\WRiYomgRmo{Yg>? NEf6Z3QzPTJ5NECzOC=>
K-562  NYr4XXJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXITWM2OD1zIN88US=> M3qze|I2OjN7Nk[y
K562  M3HRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnkO3BpUUN3ME2wMlXDqM7:TR?= NIP6c48zPDl|OUSxPC=>
K562r NWPVR2VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELuXXVKSzVyPUGwxsDPxE1? MmntNlQ6Ozl2MUi=
K562 NV\ONmZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonVSWM2OD1yLkC5JO69VQ>? Moq0NVY3Pzh2MUS=
K562 M2frRmN6fG:2b4jpZ4l1gSCDc4PhfS=> NFr5WGIzPCCq NXr3[4tFUUN3ME2wMlIyKM7:TR?= NX3mSJVROjJyMECyNFc>
MCF-7 M2nRO2N6fG:2b4jpZ4l1gSCDc4PhfS=> MoT6NlQhcA>? NV\xdWpJUUN3ME2wMlg{KM7:TR?= NYXuRXZtOjJyMECyNFc>
MDA-MB-23 M2m2OmN6fG:2b4jpZ4l1gSCDc4PhfS=> NGTYZnIzPCCq MnnITWM2OD1zLkig{txO NUXi[pBHOjJyMECyNFc>
GIST882 NGDHSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vFRVk3KGh? M3X4PGlEPTB;MT63JO69VQ>? MlP6NlQ6ODB{MUK=

... Click to View More Cell Line Experimental Data

In vivo Imatinib produces a different antitumor effect on three xenografted tumors derived from surgical samples of fresh human small cell lung cancers, with 80%, 40% and 78% growth inhibition of SCLC6, SCLC61 and SCLC108 tumors, respectively, and no significant inhibition of SCLC74 growth. [5] In high fat fed ApoE(-/-) mice, Imatinib significantly reduces the high fat-induced lipid staining area by 30%, 27% and 35% compared to high-fat diet untreated controls when dosed by gavage at 10, 20 and 40 mg/kg, respectively, and suppresses carotid artery lipid accumulation. [6]

Protocol

Kinase Assay:[1]
+ Expand

PDGF receptor kinase activity:

PDGF receptor is immunoprecipitated from BALB/c 3T3 cell extracts with rabbit antiserum to the murine PDGF receptor for 2 hours on ice. Protein A-Sepharose beads are used to collect the antigen-antibody complexes. The immunoprecipitates are washed twice with TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), once with TNE (50 mM Tris, pH 7.5, 140 mM EDTA), and once with kinase buffer (20 mM Tris, pH 7.5,10 mM MgCl2). After stimulation with PDGF (50 ng/mL) for 10 minutes at 4 °C, different concentrations of drug are added to the reaction mixture. PDGF receptor kinase activity is determined by incubation with 10 μCi [7-33P]-ATP and l μM ATP for 10 minutes at 4 °C. Immune complexes are separated by SDS-PAGE on 7.5% gels.
Cell Research:[3]
+ Expand
  • Cell lines: BON-1 cells and NCI-H727 cells
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method: BON-1 cells and NCI-H727 cells are seeded into flat-bottomed 96-well plates in triplicate and allowed to adhere overnight in 10% fetal bovine serum-supplemented DMEM or RPMI 1640 complete medium, respectively; the medium is then exchanged for serum-free medium (negative control) or serum-free medium containing serial dilutions of Imatinib. After 48 hours (control cultures do not reach confluence), the number of metabolically active cells is determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and absorbance is measured in a Packard Spectra microplate reader at 540 nm. Growth inhibition is calculated using the following formula: inhibition rate = (1 − a / b) × 100%, where a and b are the absorbance values of the treated and control groups, respectively.
    (Only for Reference)
Animal Research:[5]
+ Expand
  • Animal Models: SCLC6, SCLC61, SCLC 74 and SCLC108 small cell lung cancers are injected into Swiss mice (nu/nu, female).
  • Formulation: Imatinib is diluted in water.
  • Dosages: 70 or 100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 118 mg/mL (200.09 mM)
Water 118 mg/mL (200.09 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 589.71
Formula

C29H31N7O.CH4SO3

CAS No. 220127-57-1
Storage powder
in solvent
Synonyms CGP-57148B, ST-1571 Mesylate

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03674099 Recruiting Multiple Sclerosis Tomas Olsson|The Swedish Research Council|Karolinska Institutet October 1 2018 Phase 2
NCT03516279 Recruiting Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Minimal Residual Disease ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group October 3 2018 Phase 2
NCT03674099 Recruiting Multiple Sclerosis Tomas Olsson|The Swedish Research Council|Karolinska Institutet October 1 2018 Phase 2
NCT03516279 Recruiting Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Minimal Residual Disease ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group October 3 2018 Phase 2
NCT03688568 Recruiting Neurofibroma Plexiform Indiana University|Food and Drug Administration (FDA) September 1 2018 Phase 2
NCT03688568 Recruiting Neurofibroma Plexiform Indiana University|Food and Drug Administration (FDA) September 1 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products4

Tags: buy Imatinib Mesylate (STI571) | Imatinib Mesylate (STI571) supplier | purchase Imatinib Mesylate (STI571) | Imatinib Mesylate (STI571) cost | Imatinib Mesylate (STI571) manufacturer | order Imatinib Mesylate (STI571) | Imatinib Mesylate (STI571) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID